The Thesis
Summary
Merck & Co is a global drug manufacturer that dominates the cancer treatment market through its blockbuster medicine, Keytruda. It generated $64.93 billion in revenue in 2025, which represents a 1% increase over the prior year. While its headline growth looks slow, the company is currently making a massive financial push into new biotech acquisitions to prepare for the future.
The core bet on Merck is that its pipeline of new cardiovascular drugs and expanded cancer treatments can replace the revenue from Keytruda before its patents expire in 2028. Merck is spending billions on acquisitions like Cidara and Verona Pharma to diversify its portfolio away from a single dominant drug. If these new products scale successfully, the company will maintain its high margins while growing its footprint in vaccines and animal health. More specifically, four things need to be true:
Merck is a high-quality pharmaceutical business that is being unfairly discounted because the market is too focused on a patent cliff that is still three years away. The underlying growth in its oncology and animal health units remains strong enough to bridge the gap.
Numbers at a Glance
What does it do?
Merck & Co is a mature business that earns money by researching, developing, and selling prescription medicines and animal health products. The company operates a high-margin model where it spends heavily on research to discover new drugs, patents them to prevent competition, and sells them to hospitals and clinics. Patients and healthcare providers pay for these drugs through insurance companies or government health programs. A smaller but steady portion of the business comes from selling vaccines and medicines for pets and livestock.
Where does revenue come from?
The vast majority of revenue comes from human health medicines, specifically cancer treatments and vaccines. Oncology is the largest contributor, followed by the vaccines unit which includes the Gardasil line for preventing certain cancers. The Animal Health segment provides a secondary source of revenue through vaccines and parasite treatments for animals. According to the latest results, roughly half of all sales happen in the United States, with the remainder coming from international markets like China and Europe.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Merck & Co serves millions of patients through healthcare providers and treats hundreds of thousands of animals through veterinarians and farmers. Its primary oncology drug, Keytruda, generated $8.03 billion in sales in the first quarter of 2026 alone. The company also reached significant scale in its vaccine business, though Gardasil sales recently fell 19% to $1.07 billion due to lower demand in China. Its Animal Health division remains a steady contributor, generating $1.79 billion in quarterly sales across its companion animal and livestock portfolios.
What gives it staying power?
Merck & Co has staying power because its massive library of patents prevents competitors from selling identical drugs for many years. This intellectual property creates a legal monopoly on its most successful treatments. Even after patents expire, its manufacturing scale and deep relationships with global hospital systems make it very difficult for new players to enter.
Where is it headed?
Merck is headed toward a more diversified future where it relies less on a single cancer drug and more on a broad range of specialty biologics. Management is currently spending billions on acquisitions to build a leading position in cardiovascular and respiratory medicine. If these bets work, the company will have a fresh set of patented drugs to drive growth through the 2030s.
Bold sentence: revenue is growing at a steady low-single-digit pace as new drugs begin to contribute. Sales reached $16.29 billion in the latest quarter, representing 5% growth as oncology strength offset vaccine declines. This shows the portfolio is resilient even when individual products face temporary setbacks.
Bold sentence: free cash flow remains lumpy because Merck is aggressively buying smaller drug companies. While FCF was $12.36 billion last year, large charges for acquisitions like Cidara frequently depress reported earnings. This is a deliberate choice to use cash now to secure revenue for the next decade.
Bold sentence: the balance sheet is managed with a moderate debt-to-equity ratio of 1.07x. Merck carries significant debt to fund its research and acquisitions, but its high margins and steady cash flow keep this manageable. The company prioritizes funding the dividend and research over rapid debt repayment.
Merck is a financially strong business that is trading short-term reported losses for long-term pipeline value.
The oncology business continues to grow at a double-digit rate with Keytruda sales up 12% to $8.03 billion. This growth is being supported by a successful launch of a new subcutaneous version that patients can take more easily. The underlying demand for cancer treatments remains high regardless of the broader economy.
Vaccine sales in China are a major risk after Gardasil revenue dropped 19% in the latest quarter. Management attributed this to changing purchasing patterns, but a prolonged slump would hurt Merck's most profitable vaccine line. Investors should track whether demand recovers in the next two quarters.
The global pharmaceutical market is roughly $1.6 trillion today, growing at about 4% annually, and is on track to reach $1.9 trillion by 2029. This is a highly stable industry where pricing power is protected by government-regulated patents rather than simple market competition. Merck & Co stands as a dominant leader in the oncology sub-sector, which is the fastest-growing and most profitable part of the entire drug market. Its position as a leader in life-saving treatments gives it a long runway for growth even as older medicines lose their protection.
Competition in the drug industry is intense during the research phase but very low once a drug is approved and patented. The main threat to pricing power is not other companies, but government regulation and the eventual expiration of patent laws.
Merck faces its most direct threats from Bristol-Myers Squibb(BMY) and Pfizer(PFE), who both have large oncology and vaccine portfolios. The most dangerous threat is the rise of low-cost generic versions of Keytruda, which will become a reality after 2028 if Merck cannot move patients to newer versions. Other rivals are also trying to combine their own drugs with Merck's to take a share of the cancer treatment market.
Merck is currently holding its ground in oncology while gaining significant share in the cardiovascular market. Its new drug, Winrevair, grew 88% in the most recent quarter, proving Merck can successfully launch new products outside its core cancer business.
The primary source of Merck's protection is its massive library of intellectual property and patents. These legal protections give Merck the exclusive right to sell treatments like Keytruda, which currently accounts for nearly half of total company sales. This moat is reinforced by a regulatory hurdle that costs billions of dollars and many years to clear, preventing any small competitor from entering the market.
Merck's financial metrics prove the strength of this advantage. A gross margin of nearly 76% and a double-digit return on invested capital show that Merck does not have to compete on price to win customers. These numbers are typical of a company with a wide moat that can maintain high profits even while spending billions on research.
The moat is currently stable but faces a significant test as the Keytruda patent cliff approaches in 2028.
Raised sales guidance for FY2026 after strong Q1 results.
Spent $9 billion on Cidara to secure the oncology pipeline.
CEO holds significant stock and pay is tied to R&D milestones.
Capital Allocation Track Record
Robert Davis has done an excellent job of managing the transition toward a post-Keytruda future. The company has consistently met its financial targets while making aggressive, smart acquisitions to fill the pipeline. Management's decision to raise sales guidance in early 2026 shows high confidence in their execution. They are prioritizing long-term survival over short-term earnings growth, which is exactly what a pharmaceutical leader should do.
© 2026 ClearThesis.ai · Report generated on May 31, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.